Noubar Afeyan, Director at Moderna, Inc. (MRNA), sold 28,900 shares at $107.16 ($3.1M) on 2024-04-24, disclosed to the SEC on 2024-04-26.
Scheduled sale ($3.1M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $107.16 | 3,926 | $421K | 13.4% |
| 2 | $107.16 | 3,926 | $421K | 13.4% |
| 3 | $108.30 | 5,821 | $630K | 20.1% |
| 4 | $108.30 | 5,821 | $630K | 20.1% |
| 5 | $109.04 | 4,153 | $453K | 14.5% |
| 6 | $109.04 | 4,153 |
| $453K |
| 14.5% |
| 7 | $109.91 | 1,100 | $121K | 3.9% |
| Total | $108.26 avg | 28,900 | $3.1M | 100% |
| Filing → |
| MRNA | SELL | 2025-12-15 | $1.4M | — | Filing → |
| MRNA | SELL | 2024-08-02 | $3.6M | — | Filing → |
| MRNA | SELL | 2024-07-26 | $2.9M | — | Filing → |